retatrutide 3 receptors RETATRUTIDE: A Medication for Diabetes and Weight Loss Retatrutide 8 mg – Triple

References Frias JP, Bonora E, Nevarez Ruiz L, et al

Studies have examined retatrutide in the context of incretin and glucagon pathway signaling using preclinical and clinical models

Compared to natural ligands, retatrutide shows lower potency at GLP-1 and glucagon receptors but higher potency at GIP receptors

It's a catastrophic failure at the molecular level

Prescribers should be notified if clients experience hypoglycemia so they can lower the dose of the medication thats likely contributing most to hypoglycemia (insulin or sulfonylurea) or omit it altogether

If youre considering GLP-1 treatment or have questions about your current medication, the team at Yorktown Health is here to help